These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22390871)

  • 1. Promising option in the prevention of idiopathic anaphylaxis: omalizumab.
    Demirtürk M; Gelincik A; Colakoğlu B; Dal M; Büyüköztürk S
    J Dermatol; 2012 Jun; 39(6):552-4. PubMed ID: 22390871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
    Rottem M
    J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab and hypersensitivity reactions.
    Shankar T; Petrov AA
    Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting.
    Palgan K; Bartuzi Z; Gotz-Zbikowska M
    Int J Immunopathol Pharmacol; 2014; 27(1):109-12. PubMed ID: 24674685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher levels of soluble Fas ligand and transforming growth factor-β after omalizumab treatment: a case report.
    Kao SL; Yu HR; Kuo HC; Tsui KY; Wu CC; Chang LS; Liang CD; Chung YH; Yang KD
    J Microbiol Immunol Infect; 2012 Feb; 45(1):69-71. PubMed ID: 22244736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of severe asthma and peach allergy that improved with omalizumab therapy: a case report].
    Suzuki S; Matsuura T; Kimura T; Tazaki T; Fukuda M; Homma T; Matsukura S; Kurokawa M; Adachi M
    Arerugi; 2012 Feb; 61(2):215-23. PubMed ID: 22437731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in the treatment of chronic urticaria.
    Francés L; Leiva-Salinas M; Silvestre JF
    Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.
    Kerzel S; Zemlin M; Rogosch T; Ollert M; Renz H; Klaus G; Maier RF
    Klin Padiatr; 2011 Nov; 223(6):356-9. PubMed ID: 22012605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic autoimmune urticaria with omalizumab.
    Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
    Wu KCP; Jabbar-Lopez ZK
    J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
    Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
    Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
    Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
    Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey.
    Büyüköztürk S; Gelincik A; Demirtürk M; Kocaturk E; Colakoğlu B; Dal M
    J Dermatol; 2012 May; 39(5):439-42. PubMed ID: 22221177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.
    Uysal P; Eller E; Mortz CG; Bindslev-Jensen C
    J Allergy Clin Immunol; 2014 Mar; 133(3):914-5.e2. PubMed ID: 24360324
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
    Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
    Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.